Foundayo (orforglipron) is Eli Lilly's new once-daily pill version of a GLP-1 weight-loss medication, FDA-approved for adults with obesity or overweight with a weight-related health condition. Unlike Ozempic, Wegovy, Mounjaro, or Zepbound — all injections — Foundayo is a small-molecule tablet that can be taken any time of day, with or without food or water restrictions.
Foundayo (orforglipron) is a once-daily, small-molecule (non-peptide) oral GLP-1 receptor agonist made by Eli Lilly. It's approved for adults with obesity, or overweight with at least one weight-related medical condition, to help lose excess weight and keep it off when combined with diet and exercise.
How Does Foundayo Work?
GLP-1 (glucagon-like peptide-1) is a natural gut hormone that slows stomach emptying, increases feelings of fullness, and reduces appetite. Orforglipron activates the same GLP-1 receptor pathway that injectable GLP-1 medications (like semaglutide and tirzepatide) use — but because it's a small molecule rather than a peptide, it can be manufactured as a stable tablet and absorbed through the gut without the food and water restrictions that earlier oral GLP-1 attempts have required.
How Is Foundayo Different from Ozempic, Wegovy, Mounjaro, and Zepbound?
All of these medications work on the GLP-1 pathway, but Foundayo is the first one available as a conventional pill with no special food or water timing rules. See our full GLP-1 medications guide for how all of these compare side by side.
| Medication | Molecule | Form | Approved For |
|---|---|---|---|
| Foundayo | Orforglipron | Oral tablet, any time of day | Weight management |
| Ozempic | Semaglutide | Weekly injection | Type 2 diabetes |
| Wegovy | Semaglutide | Weekly injection | Weight management |
| Mounjaro | Tirzepatide | Weekly injection | Type 2 diabetes |
| Zepbound | Tirzepatide | Weekly injection | Weight management |
Dosing and Titration
Like other GLP-1 medications, Foundayo is started at a low dose and gradually increased to reduce GI side effects. The typical titration schedule is:
| Timeframe | Dose |
|---|---|
| First ~30 days | 0.8 mg once daily |
| Next ~30 days | 2.5 mg once daily |
| Next ~30 days | 5.5 mg once daily |
| Further increases, as needed and tolerated | 9 mg → 14.5 mg → 17.2 mg once daily (maximum) |
Your provider will decide how far to titrate based on your weight-loss response and side effects — not everyone needs the highest available dose. Tablets are swallowed whole (do not break, crush, or chew) and can be taken with or without food, at any time of day.
Side Effects
The most common side effects, similar to other GLP-1 medications, are gastrointestinal: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, bloating, belching, gas, and heartburn — most noticeable during dose increases and often improving over time. Headache, fatigue, and hair loss have also been reported.
⚠️ Warnings: Foundayo carries the same class warnings as other GLP-1 medications: a risk of thyroid C-cell tumors seen in animal studies (it should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), pancreatitis, severe gastrointestinal reactions, gallbladder problems, dehydration-related kidney injury, and low blood sugar when combined with insulin or sulfonylureas.
Who Might Consider Foundayo?
Foundayo may appeal to patients who want the metabolic benefits of a GLP-1 medication but prefer to avoid injections, have needle anxiety, or want the flexibility of a pill they can take without cold-chain storage or injection supplies. As with any weight-management medication, your endocrinologist will review your full health history — including thyroid and pancreas history — before prescribing.
Key Takeaways
- Foundayo (orforglipron) is the first oral small-molecule GLP-1 medication, FDA-approved for weight management
- Works the same way as injectable GLP-1 medications, but as a once-daily pill with no food or water restrictions
- Started at 0.8 mg daily and gradually titrated up to a maximum of 17.2 mg daily, based on response and tolerance
- Most common side effects are gastrointestinal (nausea, constipation, diarrhea) and typically improve over time
- Carries the same class warnings as other GLP-1 medications, including thyroid tumor risk in animal studies and pancreatitis
- Not for patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
Our Team Can Help
All five of our providers diagnose and manage endocrine conditions. Book with any member of our team:
Book an Appointment → or call 832-968-7003